These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 17461818)

  • 1. Generalized erythrodermic pemphigus foliaceus in a child and its successful response to rituximab treatment.
    Connelly EA; Aber C; Kleiner G; Nousari C; Charles C; Schachner LA
    Pediatr Dermatol; 2007; 24(2):172-6. PubMed ID: 17461818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of refractory pemphigus with the anti-CD20 monoclonal antibody (rituximab).
    Marzano AV; Fanoni D; Venegoni L; Berti E; Caputo R
    Dermatology; 2007; 214(4):310-8. PubMed ID: 17460402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab in refractory pemphigus vulgaris.
    Sorce M; Aricò M; Bongiorno MR
    Dermatol Ther; 2008 Jul; 21 Suppl 1():S6-9. PubMed ID: 18727815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful treatment of refractory childhood pemphgus vulgaris with anti-CD20 monoclonal antibody (rituximab).
    Kong HH; Prose NS; Ware RE; Hall RP
    Pediatr Dermatol; 2005; 22(5):461-4. PubMed ID: 16191003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonendemic pemphigus foliaceus presenting as fatal bullous exfoliative erythroderma.
    Nousari HC; Moresi M; Klapper M; Anhalt GJ
    Cutis; 2001 Mar; 67(3):251-2. PubMed ID: 11270302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus.
    Arin MJ; Engert A; Krieg T; Hunzelmann N
    Br J Dermatol; 2005 Sep; 153(3):620-5. PubMed ID: 16120153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A case of non-Hodgkin's lymphoma-associated pemphigus foliaceus and use of rituximab for treatment.
    Prodanovic EM; Korman NJ
    J Dermatolog Treat; 2008; 19(6):1-3. PubMed ID: 18720187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab: a monoclonal antibody to CD20 used in the treatment of pemphigus vulgaris.
    El Tal AK; Posner MR; Spigelman Z; Ahmed AR
    J Am Acad Dermatol; 2006 Sep; 55(3):449-59. PubMed ID: 16908351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of severe pemphigus with rituximab: report of 12 cases and a review of the literature.
    Cianchini G; Corona R; Frezzolini A; Ruffelli M; Didona B; Puddu P
    Arch Dermatol; 2007 Aug; 143(8):1033-8. PubMed ID: 17709662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy and safety of rituximab in refractory pemphigus: a review of case reports.
    Allen KJ; Wolverton SE
    J Drugs Dermatol; 2007 Sep; 6(9):883-9. PubMed ID: 17941359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-B- cell-directed immunotherapy (rituximab) in the treatment of refractory pemphigus--an update.
    Arin MJ; Hunzelmann N
    Eur J Dermatol; 2005; 15(4):224-30. PubMed ID: 16048747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two courses of rituximab (anti-CD20 monoclonal antibody) for recalcitrant pemphigus vulgaris.
    Faurschou A; Gniadecki R
    Int J Dermatol; 2008 Mar; 47(3):292-4. PubMed ID: 18289336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delayed response of oral pemphigus vulgaris to rituximab treatment.
    Niedermeier A; Wörl P; Barth S; Schuler G; Hertl M
    Eur J Dermatol; 2006; 16(3):266-70. PubMed ID: 16709491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolonged treatment with rituximab in patients with refractory pemphigus vulgaris.
    Barrera MV; Mendiola MV; Bosch RJ; Herrera E
    J Dermatolog Treat; 2007; 18(5):312-4. PubMed ID: 17852643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of refractory pemphigus vulgaris with rituximab (anti-CD20 monoclonal antibody).
    Dupuy A; Viguier M; Bédane C; Cordoliani F; Blaise S; Aucouturier F; Bonnetblanc JM; Morel P; Dubertret L; Bachelez H
    Arch Dermatol; 2004 Jan; 140(1):91-6. PubMed ID: 14732665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Juvenile pemphigus vulgaris].
    Janisson-Dargaud D; Reguiaï Z; Perceau G; Eschard C; Bernard P
    Ann Dermatol Venereol; 2008 Dec; 135(12):843-7. PubMed ID: 19084695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin.
    Ahmed AR; Spigelman Z; Cavacini LA; Posner MR
    N Engl J Med; 2006 Oct; 355(17):1772-9. PubMed ID: 17065638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paraneoplastic pemphigus presenting as erythrodermic lichenoid dermatitis with concomitant features of pemphigus foliaceus.
    Fukumoto T; Shiroyama Y; Niizeki H; Kobayashi N; Asada H; Ishii N; Hashimoto T; Miyagawa S
    J Dermatol; 2007 Sep; 34(9):645-9. PubMed ID: 17727368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab in severe pemphigus.
    Schmidt E; Goebeler M; Zillikens D
    Ann N Y Acad Sci; 2009 Sep; 1173():683-91. PubMed ID: 19758216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab in refractory autoimmune bullous diseases.
    Schmidt E; Hunzelmann N; Zillikens D; Bröcker EB; Goebeler M
    Clin Exp Dermatol; 2006 Jul; 31(4):503-8. PubMed ID: 16716150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.